Based on toxicity studies in monkeys, the heart (decreased heart rate and QT prolongation), eyes (cataracts), central nervous system (ataxia, tremor, convulsion), and liver (hepatocellular hypertrophy without elevations in alanine aminotransferase [ALT] or aspartate aminotransferase [AST] activities) were identified as potential target organs for pretomanid toxicity in human subjects, as outlined in Table 2, [15]. The gene discussed is GPT; the disease is Ataxia.